In an interview at the recent RSNA conference, Catherine Everett, M.D., shared her perspective on the radiology workforce shortage, offered insights on recruiting radiologists to rural areas and emphasized the urgency of bolstering access to radiologists and other health-care professionals for at-risk communities.
In a recent interview, Mahsa Dolatshahi, M.D., M.P.H., and Cyrus A. Raji, M.D., Ph.D., discussed MRI and PET study findings, presented at the Radiological Society of North America (RSNA) conference, that showed an association between higher amyloid PET tracer uptake in the precuneus cortex and a higher visceral to subcutaneous fat ratio.
In a recent interview at the annual RSNA conference in Chicago, Richard Heller, MD discussed the impact of reduced reimbursement rates in radiology, the projected CMS conversion factor for 2024, the severity of payment cuts in interventional radiology and the importance of radiologist advocacy.
Dr. Kottler sat down with Diagnostic Imaging at RSNA 2023 to discuss AI imaging milestones and the potential impact of AI on workflows in radiology.
In a recent interview about President Biden’s recent executive order on artificial intelligence (AI), Morris Panner, the president of Intelerad Medical Systems, shared his concerns that the executive order, while well-intentioned, may wind up stifling innovation and the continued evolution of AI in radiology.
Radiology experts discuss the current knowledge and use of PSMA-PET screening among colleagues, as well as unmet needs.
Imaging experts compare gallium-based agents to non–gallium-based agents for prostate cancer screening.
Experts highlight gallium-based and PyL PSMA-PET scans for use in prostate cancer, commenting on approvals as well as how the agents are made.
Two experts review SNMMI (Society of Nuclear Medicine and Molecular Imaging) guidelines for use of PSMA PET scans in prostate cancer detection, as well as awareness about this new modality within the patient community.
Experts highlight the use of PSMA PET scans as a recent and accurate imaging method for prostate cancer screening.
Imaging experts discuss the challenges with traditional imaging modalities for prostate cancer, commenting on the bone scan and CT scan.
Experts review traditional imaging modalities for prostate cancer, highlighting the most commonly used modalities.
In a recent video interview, Vivek Bansal, M.D., discussed a recent Radiology Partners publication that offers practical tips and best practice guidance on CT and MRI neuroimaging for stroke patients.
Joseph Cavallo, MD, MBA, and Dushyant Sahani, MD, discuss unmet needs in imaging modality technology and the contrasting agents used.
Experts discuss discuss the American College of Radiology recommendations regarding the use of contrast media and their guidance related to the use of generics during supply shortages.
Joseph Cavallo, MD, MBA, and Dushyant Sahani, MD, discuss generic agents iodixanol injection and gadoterate meglumine injection for the use in imaging modalities.
Experts discuss the concept of generics and how they have traditionally been utilized in the healthcare space.
Joseph Cavallo, MD, MBA, and Dushyant Sahani, MD, provide an overview of the different imaging technique protocols needed for contrast agents.
In interviews at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) conference, researchers discussed the potential impact of ultra-high resolution brain positron emission tomography (PET) as well as emerging PET radiotracers for detecting coronary artery disease in obese patients and diagnosing clear cell renal cell carcinoma.
Radiology experts discuss the role of contrast agents in imaging and the impact these agents have on image quality.
Joseph Cavallo, MD, MBA, and Dushyant Sahani, MD, provide a brief overview of imaging modalities and their importance in medical diagnosis and treatment.
In a video interview, Hong Song, M.D., Ph.D., discussed retrospective research, presented at the recent Society for Nuclear Medicine and Molecular Imaging (SNMMI) conference, that evaluated the combination of artificial intelligence (AI)-based software and the PSMA agent piflufolastat F 18 to help quantify prostate cancer lesions and associations with biochemical progression-free survival.
In a video interview, Jacob Dubroff, M.D., Ph.D., discussed the potential impact of the recent CMS proposal to rein in Medicare coverage restrictions on the use of amyloid positron emission tomography (PET) for patients with Alzheimer’s disease.
In a recent interview at the SNMMI conference, Roger Lecomte, Ph.D., and Vincent Doyon discussed the advent of ultra-high resolution (UHR) brain positron emission tomography (PET), which reportedly offers double the spatial resolution of conventional PET and may facilitate earlier detection of Alzheimer’s disease and other conditions.
In a recent interview at the SNMMI conference, Krishna Patel, M.D., discussed the benefits of the PET perfusion radiotracer agent 18F-flurpiridaz and new research findings showing the agent’s increased sensitivity and specificity in diagnosing coronary artery disease in obese patients.
The use of single-photon emission computed tomography (SPECT)/computed tomography (CT) to monitor the effectiveness of Lu-177-PSMA (Pluvicto) in treating prostate cancer led to a greater than 50 percent decrease in prostate-specific antigen (PSA) level for 60 percent of patients in a new study, noted Andrew Nguyen, MBBS, FRACP, AANMS, in a recent interview at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) conference in Chicago.
The approval of Blue Earth Diagnostics' Posluma (flotufolastat F 18) is a significant step forward for PSMA PET imaging, but will it actually help improve patient outcomes?
In an interview at the recent Society of Nuclear Medicine and Molecular Imaging (SNMMI) conference in Chicago, Jeremie Calais, M.D., MSc discussed promising research findings for the use of the positron emission tomography (PET) imaging agent 89ZR-DFO-girentuximab for diagnosing clear cell renal cell carcinoma.
In a recent interview at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) conference in Chicago, Phillip Kuo, M.D., Ph.D, F.A.C.R., discussed the potential impact of urinary activity with positron emission tomography (PET) radiopharmaceuticals, and new phase 3 study data that found low urinary activity with the use of the flotufolastat F 18 injectable agent in patients with prostate cancer.
Dr. Nadel was announced as president of SNMMI for the 2023-2024 term at the 2023 SNMMI annual meeting taking place in Chicago.
